Abstracts tagged "Bone density"

Abstract Number: 1237 • 2013 ACR/ARHP Annual Meeting
Denosumab Leads To Significantly Greater Increases In Bone Mineral Density Than Ibandronate and Risedronate In Postmenopausal Women At High Risk For Fracture Who Were Previously Treated With An Oral Bisphosphonate
Jacques P. Brown¹, Michael A. Bolognese², Pei-Ran Ho³, Jesse Hall³, Christian Roux⁴, Henry G. Bone⁵, Sydney Bonnick⁶, Joop van den Bergh⁷, Irene Ferreira⁸, Prayashi Ghelani⁹, Paula Dakin³, Rachel B. Wagman³ and Chris Recknor¹⁰, ¹CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada, ²Bethesda Health Research Center, Bethesda, MD, ³Amgen Inc., Thousand Oaks, CA, ⁴Paris Descartes University, Paris, France, ⁵Michigan Bone and Mineral Clinic, Detroit, MI, ⁶Clinical Research Center of North Texas, Denton, TX, ⁷VieCuri Medical Centre and Maastricht University, Venlo, Netherlands, ⁸Amgen Inc., Cambridge, United Kingdom, ⁹Ovatech Solutions, London, United Kingdom, ¹⁰United Osteoporosis Centers, Gainesville, GA
Denosumab Leads to Significantly Greater Increases in Bone Mineral Density Than Ibandronate and Risedronate in Postmenopausal Women at High Risk for Fracture Who Were Previously…
Abstract Number: 1239 • 2013 ACR/ARHP Annual Meeting
The Effects Of Hyperparathyroidism On Body Mass Index and Bone Mineral Density- An Observational Case-Control Study
Chris Varley¹, Alexander Oldroyd² and Marwan Bukhari³, ¹Lancaster Medical School, Lancaster University, Llandudno, United Kingdom, ²Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ³Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Hyperparathyroidism is associated with reduced bone mineral density (BMD) and increased fracture risk. A previous study from this group has shown that bone loss…
Abstract Number: 1222 • 2013 ACR/ARHP Annual Meeting
Analysis Of Corelation Of Bone Mineral Density Of Spine With Other Sites In Ankylosing Spondylitis As Compared To Rheumatoid Arthritis and Control Populations
Janie Bruce¹ and Vikas Majithia^2,3, ¹Div of Rheumatology, University of Mississippi School of Medicine, Jackson, MS, ²Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS, ³G.V. "Sonny" Montogomery VA Medical Center, Jackson, MS
Background/Purpose: Bone mineral density (BMD) at the 3 central sites usually correlates with each other but the effect of disease states on this correlation is…
Abstract Number: 1230 • 2013 ACR/ARHP Annual Meeting
Analysis Of Fracture Risk Assessment Score (FRAX) Correlation With Bone Mineral Density (BMD) In Males and Post-Menopausal Females
Vikas Majithia¹ and Khush Aujla², ¹Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS, ²Division of Rheumatology, University of Mississippi School of Medicine, Jackson, MS
Background/Purpose: Fracture Risk Assessment Tool (FRAX) is a useful clinical tool for assessment of fracture risk and a major development in evaluation of osteoporosis. Its…
Abstract Number: 1219 • 2013 ACR/ARHP Annual Meeting
Phase 3 Fracture Trial Of Odanacatib For Osteoporosis – Baseline Characteristics and Study Design
Socrates Papapoulos¹, Henry G. Bone², David W. Dempster³, John Eisman⁴, Susan Greenspan⁵, Michael McClung⁶, Toshitaka Nakamura⁷, Joseph Shih⁸, Albert Leung⁹, Arthur Santora¹⁰, N. Verbruggen¹¹ and Antonio Lombardi¹², ¹Leiden University Medical Center, Leiden, Netherlands, ²Michigan Bone and Mineral Clinic, Detroit, MI, ³Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, ⁴The Garvan Institute of Medical Research, Sydney, Australia, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Oregon Osteoporosis Center, Portland, OR, ⁷University of Occupational & Environmental Health, Fukuoaka, Japan, ⁸Robert Wood Johnson Medical School, Piscataway, NJ, ⁹Clinical Research, Merck Sharp and Dohme Corp., Rahway, NJ, ¹⁰Merck Sharp & Dohme Corp., Whitehouse Station, NJ, ¹¹MSD Belgium, Brussels, Belgium, ¹²Merck Sharp and Dohme Corp., Rahway, NJ
Background/Purpose: Odanacatib is a selective and reversible inhibitor of cathepsin K; a collagenase secreted by osteoclasts, and is currently being evaluated for the treatment of…
Abstract Number: 1221 • 2013 ACR/ARHP Annual Meeting
The Effects Of Hyperthyroidism On Bone Mineral Density At Different Sites- An Observational Case-Control Study
Christopher Varley¹, Alexander Oldroyd¹ and Marwan Bukhari², ¹Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ²Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Hyperthyroidism has been described as a risk factor for poor bone health.1, 2 The FRAXTM tool has been used to identify the ten year…
Abstract Number: 1225 • 2013 ACR/ARHP Annual Meeting
FRAX 10-Year Fracture Risk In Women With a Fracture Of The Distal Forearm: Agreement Between Assessments With and Without Bone Mineral Density and Influence Of Measurement Side In Individual Patients
Emilie Egsmose¹, Mette Birkvig², Thora Buhl³ and Ole Rintek Madsen³, ¹Copenhagen University Hospital Hvidovre, Copenhagen, Denmark, ²Osteoporosis Clinic, Copenhagen University Hospital Gentofte, Copenhagen, Denmark, ³Copenhagen University Hospital Gentofte, Copenhagen, Denmark
Background/Purpose: The FRAX® tool has been developed by WHO to evaluate fracture (Fx) risk of patients. It is based on individual patient models that integrate…
Abstract Number: 1234 • 2013 ACR/ARHP Annual Meeting
Effects Of Biological Therapy In Bone Metabolism In Patients With Chronic Inflammatory Arthropathies
Maria Victoria Hernández¹, Andrea Cuervo², Pilar Peris¹, Ana Monegal¹, Raimon Sanmarti¹, Juan D. Cañete¹ and Nuria Guañabens¹, ¹Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ²Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose: The efficacy of biological agents in the treatment of chronic inflammatory arthropathies is well known, however, the effect of this therapy in bone metabolism…
Abstract Number: 863 • 2013 ACR/ARHP Annual Meeting
Romosozumab Administration Is Associated With Significant Improvements In Lumbar Spine and Hip Volumetric Bone Mineral Density and Content Compared With Teriparatide
H K Genant¹, S Boonen², M A Bolognese³, C Mautalen⁴, J P Brown⁵, C Recknor⁶, S Goemaere⁷, K Engelke⁸, Y-C Yang⁹, M Austin⁹, A Grauer⁹ and C Libanati⁹, ¹UCSF & Synarc Inc., San Francisco, CA, ²Leuven University Division of Geriatric Medicine, Leuven, Belgium, ³The Bethesda Health Research Center, Bethesda, MD, ⁴Centro de Osteopatias Medicas, Buenos Aires, Argentina, ⁵CHU de Québec Research Centre and Laval University, Québec, QC, Canada, ⁶United Osteoporosis Centers, Gainesville, GA, ⁷Ghent University Hospital, Ghent, Belgium, ⁸Synarc Germany, Hamburg, Germany, ⁹Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. Romosozumab, a monoclonal antibody to sclerostin stimulates bone formation and decreases bone resorption. In a phase…
Abstract Number: 864 • 2013 ACR/ARHP Annual Meeting
Further Reduction In Nonvertebral Fracture Rate Is Observed Following 3 Years Of Denosumab Treatment: Results With Up To 7 Years In The Freedom Extension
Jonathan D. Adachi¹, Serge Ferrari², Carol Zapalowski³, Paul D. Miller⁴, Jean-Yves Reginster⁵, Ove Törring⁶, Nadia Daizadeh³, Andrea Wang³, Cynthia O'Malley⁷, Rachel B. Wagman³ and E. Michael Lewiecki⁸, ¹McMaster University, Hamilton, ON, Canada, ²Geneva University Hospital, Geneva, Switzerland, ³Amgen Inc., Thousand Oaks, CA, ⁴Colorado Center for Bone Research, Lakewood, CO, ⁵University of Liège, Liège, Belgium, ⁶Karolinska Institutet, Södersjukhuset, Stockholm, Sweden, ⁷Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁸New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM
Further Reduction in Nonvertebral Fracture Rate Is Observed Following 3 Years of Denosumab Treatment: Results With up to 7 Years in the FREEDOM ExtensionBackground/Purpose: Some…
Abstract Number: 865 • 2013 ACR/ARHP Annual Meeting
Vertebral Fractures In The 3 Year Period Following Steroid Initiation Among Children With Chronic Illnesses
Johannes Roth¹, Jinhui Ma¹, David A. Cabral², Peter B. Dent³, Janet E. Ellsworth⁴, Adam M. Huber⁵, Kristin M. Houghton², Roman Jurencak¹, Bianca A. Lang⁵, Maggie Larche³, Claire MA Leblanc⁶, Brian Lentle², MaryAnn Matzinger¹, Paivi M. Miettunen⁷, Kiem Oen⁸, Claire Saint-cyr⁹, Rosie Scuccimarri¹⁰, Nazih Shenouda¹, Leanne M. Ward¹ and The Canadian STOPP Consortium¹¹, ¹University of Ottawa, Ottawa, ON, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶McGill University, Montréal, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Université de Montréal, Montreal, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹National Pediatric Bone Health Working Group, Ottawa, ON, Canada
Background/Purpose: : To describe the pattern and frequency of incident vertebral fractures (VF) in glucocorticoid (GC)-treated children and to determine the clinical factors at baseline…
Abstract Number: 373 • 2013 ACR/ARHP Annual Meeting
Menopause Occurs Earlier and Is An Independent Risk Factor For Osteoporosis In Women With Rheumatoid Arthritis
Michael Cocker¹, Alexander Oldroyd² and Marwan Bukhari³, ¹Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom, ²Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ³Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) and early menopause (
Abstract Number: 1979 • 2012 ACR/ARHP Annual Meeting
Care Gap in the Treatment of Patients with High Risk for Fractures in a Single Canadian Academic Center
Arthur N. Lau¹, Michael Branch², Robert Bensen³, Jonathan D. Adachi⁴, Alexandra Papaioannou⁵, William Wong-Pack⁶ and William G. Bensen⁷, ¹Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²CEO, Inovex, Oakville, ON, Canada, ³Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁴St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Geriatric Medicine, McMaster University, Hamilton, ON, Canada, ⁶Department Of Nuclear Medicine, Hamilton, ON, Canada, ⁷Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada
Background/Purpose: A number of clinical prediction tools are available to stratify patients into low, moderate and high risk for fractures in future. These tools are…
Abstract Number: 444 • 2012 ACR/ARHP Annual Meeting
Tocilizumab Improves Bone Mineral Density Compared with Abatacept in Patients with TNF Blockers-Resistant Active Rheumatoid Arthritis. an Open Label Randomized Controlled Trial
Kensuke Kume¹, Kanzo Amano¹, Susumu Yamada¹, Kazuhiko Hatta², Kuniki Amano³, Noriko Kuwaba⁴ and Hiroyuki Ohta⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²Rheumatology, Hatta Clinic, Kure, Japan, ³Rheumatology, Sky Clinic, Hiroshima, Japan, ⁴Medical Research, Sanki Clinical Link, Hiroshima, Japan, ⁵Medical Research, hiroshima clinic, Hiroshima, Japan
Background/Purpose: To compare the effect of tocilizumab(TCZ) plus methotrexate (MTX), with the effect of abatacept(ABT) plus MTX on bone mineral density(BMD) in TNF blockers resistant…
Abstract Number: 1985 • 2012 ACR/ARHP Annual Meeting
The Effect of Calcium and Vitamin D On Bone Loss in an Epileptic Population
Philip Dussault¹, Samuel Davis Jr.² and Antonio A. Lazzari³, ¹Primary Care / Pharmacy, Boston VA HCS, Boston, MA, ²Osteoporosis, Boston VA HCS, Boston, MA, ³Prim Care/Rheumatology, Boston VA Medical Center, Boston, MA
Background/Purpose: Accelerated rate of bone loss leading to osteopenia and osteoporosis is a well recognized adverse effect of long term anticonvulsant use, particularly phenytoin,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].